Logo image of NMTC

NEUROONE MEDICAL TECHNOLOGIE (NMTC) Stock Fundamental Analysis

NASDAQ:NMTC - Nasdaq - US64130M2098 - Common Stock - Currency: USD

0.7486  -0.01 (-1.5%)

Fundamental Rating

2

Taking everything into account, NMTC scores 2 out of 10 in our fundamental rating. NMTC was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NMTC may be in some trouble as it scores bad on both profitability and health. NMTC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NMTC had negative earnings in the past year.
NMTC had a negative operating cash flow in the past year.
In the past 5 years NMTC always reported negative net income.
NMTC had a negative operating cash flow in each of the past 5 years.
NMTC Yearly Net Income VS EBIT VS OCF VS FCFNMTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

NMTC has a worse Return On Assets (-148.22%) than 88.77% of its industry peers.
Looking at the Return On Equity, with a value of -586.72%, NMTC is doing worse than 88.24% of the companies in the same industry.
Industry RankSector Rank
ROA -148.22%
ROE -586.72%
ROIC N/A
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
NMTC Yearly ROA, ROE, ROICNMTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K -2K

1.3 Margins

Looking at the Gross Margin, with a value of 69.88%, NMTC is in the better half of the industry, outperforming 79.68% of the companies in the same industry.
NMTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMTC Yearly Profit, Operating, Gross MarginsNMTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NMTC has been increased compared to 1 year ago.
NMTC has more shares outstanding than it did 5 years ago.
NMTC has a worse debt/assets ratio than last year.
NMTC Yearly Shares OutstandingNMTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NMTC Yearly Total Debt VS Total AssetsNMTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -19.36, we must say that NMTC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NMTC (-19.36) is worse than 88.77% of its industry peers.
NMTC has a Debt/Equity ratio of 1.21. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.21, NMTC is not doing good in the industry: 82.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Altman-Z -19.36
ROIC/WACCN/A
WACC8.77%
NMTC Yearly LT Debt VS Equity VS FCFNMTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

NMTC has a Current Ratio of 2.13. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.
NMTC has a Current ratio of 2.13. This is in the lower half of the industry: NMTC underperforms 62.57% of its industry peers.
NMTC has a Quick Ratio of 1.09. This is a normal value and indicates that NMTC is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of NMTC (1.09) is worse than 74.33% of its industry peers.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 1.09
NMTC Yearly Current Assets VS Current LiabilitesNMTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.44% over the past year.
Looking at the last year, NMTC shows a very strong growth in Revenue. The Revenue has grown by 132.49%.
NMTC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 143.22% yearly.
EPS 1Y (TTM)61.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)132.49%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%0.72%

3.2 Future

The Earnings Per Share is expected to grow by 20.23% on average over the next years. This is a very strong growth
Based on estimates for the next years, NMTC will show a very strong growth in Revenue. The Revenue will grow by 34.68% on average per year.
EPS Next Y69.05%
EPS Next 2Y28.17%
EPS Next 3Y20.23%
EPS Next 5YN/A
Revenue Next Year24.43%
Revenue Next 2Y32.83%
Revenue Next 3Y35.36%
Revenue Next 5Y34.68%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NMTC Yearly Revenue VS EstimatesNMTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 5M 10M 15M 20M
NMTC Yearly EPS VS EstimatesNMTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NMTC. In the last year negative earnings were reported.
Also next year NMTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMTC Price Earnings VS Forward Price EarningsNMTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMTC Per share dataNMTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

NMTC's earnings are expected to grow with 20.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.17%
EPS Next 3Y20.23%

More info and screens

0

5. Dividend

5.1 Amount

NMTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROONE MEDICAL TECHNOLOGIE

NASDAQ:NMTC (8/8/2025, 8:00:02 PM)

0.7486

-0.01 (-1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-14 2025-08-14/bmo
Inst Owners10.96%
Inst Owner Change174.02%
Ins Owners4.25%
Ins Owner Change4.48%
Market Cap37.30M
Analysts85.71
Price Target1.48 (97.7%)
Short Float %0.4%
Short Ratio0.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)91.29%
Min EPS beat(2)23.75%
Max EPS beat(2)158.82%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.72%
Min Revenue beat(2)-43.22%
Max Revenue beat(2)52.66%
Revenue beat(4)1
Avg Revenue beat(4)-34.64%
Min Revenue beat(4)-88.49%
Max Revenue beat(4)52.66%
Revenue beat(8)3
Avg Revenue beat(8)-9.26%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)28.57%
EPS NY rev (1m)0%
EPS NY rev (3m)53.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-32.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-34.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.26
P/FCF N/A
P/OCF N/A
P/B 33.12
P/tB 34.86
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.18
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -148.22%
ROE -586.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.88%
FCFM N/A
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.97
Health
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.2%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.13
Quick Ratio 1.09
Altman-Z -19.36
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)158.25%
Cap/Depr(5y)160.45%
Cap/Sales(3y)9.28%
Cap/Sales(5y)12.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y69.05%
EPS Next 2Y28.17%
EPS Next 3Y20.23%
EPS Next 5YN/A
Revenue 1Y (TTM)132.49%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%0.72%
Revenue Next Year24.43%
Revenue Next 2Y32.83%
Revenue Next 3Y35.36%
Revenue Next 5Y34.68%
EBIT growth 1Y49.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.65%
OCF growth 3YN/A
OCF growth 5YN/A